High-dose-rate afterloading brachytherapy in carcinoma of the cervix: an experience of 1992 patients

Lorvidhaya, Vicharn; Tonusin, Anun; Changwiwit, W; Chitapanarux, Imjai; Srisomboon, Jatupol; Wanwilairat, Somsak; Chawapun, Nisa; Sukthomya, Vimol

doi:10.1016/s0360-3016(99)00383-1

Cited by 52 publications

(23 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of HDR as an alternative to LDR for all stages of cervical carcinoma has been reported in a number of retrospective series [23][24][25][26][27][28][29][30][31][32][33][34][35][36] and four randomized prospective trials. [37][38][39][40] However, the data comparing HDR to LDR for cancer of the cervix are fraught with bias and may be difficult to compare because of a lack of detailed information on the radiation administered and a wide range of externalbeam and intracavitary dose and fractionation schedules.…”

Section: Brachytherapy For Stage III Cervical Cancermentioning

confidence: 99%

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Stewart¹,

Viswanathan²

2006

Cancer

View full text Add to dashboard Cite

The use of brachytherapy in the treatment of cervical cancer has increased worldwide since its initial introduction over 100 years ago. However, certain aspects of the use of high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy continue to be controversial, particularly the role of HDR in FIGO Stage III cervical cancer and the use of HDR with concurrent chemotherapy. This study represents a systematic literature review of prospective and retrospective series of patients with cervical carcinoma treated with external-beam radiation

show abstract

Section: Brachytherapy For Stage III Cervical Cancermentioning

confidence: 99%

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Stewart¹,

Viswanathan²

2006

Cancer

View full text Add to dashboard Cite

show abstract

“…According to caio et al, 5 year survival for stage I, II, III reported was 74%,56%,33% respectively [24]. The overall 5 years survival after radiotherapy for cervical cancer was 68.2% for all stages and being 86.3, 81.1, 73.0, 50.3, 47.8 and 7.8% for stages IB, IIA, IIB, IIIA, IIIB and IVA respectively as reported by Lorvidhyal [25]. Another study by Benedet showed survival of 95%, 80%, 63%, 36% and 15% respectively for stages IA, IB, II, III and IV respectively [26].…”

Section: Discussionmentioning

confidence: 77%

Determinants of Survival of Cervical Cancer: A Hospital Based Study

Rani¹,

Singh²

2017

Gynecol Obstet

View full text Add to dashboard Cite

Globally uterine cervix cancer is one of the leading causes of death in females due to cancer, especially in developing countries. The aim of the study was to analyse the survival as well as understanding various prognostic factors for survival in patients of carcinoma cervix presenting in our hospital. A total of 508 patients were evaluated in radiotherapy department of Mahavir Cancer Sansthan and Research centre Patna, Bihar who came for follow up between April 2015 to March 2016 after completion of radical radiotherapy. Out of 508 patients 3.54% (n 18), 71.65% (n 364), 22.83% (n 116) and 1.9% (n 10) patients presented in sage I, II, III and IV A respectively. 53.54% of patients belonged to age group of 35 to 50 years with Survival of 937 ± 53.49 days. 46.46% of the patients were more than 50 years age and their survival was 933.3 ± 57.12 days. The mean duration for overall survival for all cases evaluated was 957.4 ± 39.49 days. The mean duration for survival of stages I, II, III and IVA was 1186 ± 281.8 days, 960 ± 85.04 days, 945.1 ± 45.66 days and 765 ± 181.5 days respectively. Survival of patients having squamous cell carcinoma was 970 ± 42.89 days and that of adenocarcinoma was 669.5 ± 120 days and that of premenopausal and postmenopausal lady was 997.5 ± 79.28 and 940.1 ± 45.39 days respectively. It was evident from study that patients who presented in early stage had a better survival. There was no significant difference in survival of cervix cancer patients in different age groups while survival was greater in premenopausal cervical cancer patients.

show abstract

“…The factors influencing overall survival are tumor size, staging, hemoglobin level, interval between external-intracavitary radiation and radiotherapy (Pomros et al, 2007). The overall 5 year survival rate of stage IIIB cervical cancer by using CCPR was 52% when compared with 34-54.8% of historic controls (Arai et al, 1992;Lorvidhaya et al, 2000;Rose et al, 2007;Wong et al, 2003;Pesee et al, 2010). In addition, the overall 3 year survival rate of 3D conformal radiotherapy with or without chemotherapy plus image (MRI) guided adaptive intracavitary brachytherapy was 45% for stage IIIB cervical cancer (Potter et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Palliative Treatment of Advanced Cervical Cancer with Radiotherapy and Thai Herbal Medicine as Supportive Remedy - Analysis of Survival

Pesee

Kirdpon²,

Puapairoj³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

High-dose-rate afterloading brachytherapy in carcinoma of the cervix: an experience of 1992 patients

Cited by 52 publications

References 21 publications

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Determinants of Survival of Cervical Cancer: A Hospital Based Study

Palliative Treatment of Advanced Cervical Cancer with Radiotherapy and Thai Herbal Medicine as Supportive Remedy - Analysis of Survival

Contact Info

Product

Resources

About